SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp (UAMY) is trending as its new joint venture with Americas Gold and Silver for a state-of-the-art hydromet plant and a crucial DLA contract highlight its role in securing domestic critical mineral supply. The community is keenly observing its potential amidst government initiatives to reduce foreign dependency, even as discussions about market manipulation and short selling persist.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing a surge following positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, leading to active community discussions around its potential and contributing to a broader biotech sector rally.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is caught in a market-wide software sector sell-off, with intense debate among investors over whether AI advancements pose an existential threat to its core business or if the stock is now massively oversold, presenting a generational buying opportunity given its strong fundamentals and significant buyback potential.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is a trending topic following its recent earnings, which included a revenue miss but an EPS beat, sparking a community debate between those who see it as an undervalued fintech player with a promising management turnaround plan and others concerned about its debt, shrinking margins, and the broader industry's vulnerability to AI.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog's strong Q4 earnings beat is sparking investor conversation, contrasting with softer full-year guidance that has some questioning its valuation and competitive landscape. The market is debating whether its AI-driven growth can lead a broader software sector rebound, or if recent sell-offs reflect ongoing headwinds.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as its latest earnings report revealed a wider Q4 loss, yet this is largely overshadowed by strong 2026 profitability guidance and record membership growth. Community sentiment is divided between optimism for market share expansion and skepticism regarding the ambitious future projections in a volatile healthcare sector.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following a strong earnings report that showcased robust revenue and GMV growth, significantly reduced cash burn, and a clear path to profitability by late 2026. The community is buzzing about this financial turnaround and recent analyst upgrades touting Jumia as the "Amazon of Africa" in an accelerating e-commerce market.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following an impressive earnings beat, robust subscriber growth, and strong guidance, which has prompted multiple analyst upgrades and fueled community excitement for a significant rebound. Despite ongoing competitive pressures and recent price adjustments, investors are focusing on improved profitability and potential for a sustained upside.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending after pre-announcing preliminary revenue significantly above prior guidance, signaling accelerating demand from hyperscale customers and AI networking. The community is highly bullish, viewing this strong beat as validation for its critical role in the ongoing AI infrastructure build-out.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is generating significant buzz following strong positive maintenance data for its rezpegaldesleukin in atopic dermatitis, with the community actively discussing its potential as a game-changer against competitors and fueling buyout speculation amidst an ongoing lawsuit with Lilly, all while eagerly anticipating upcoming alopecia areata trial results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Hold" by Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are presently covering the stock, Marketbeat...

New Strong Sell Stocks for January 30th

TSE, PAC and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 30th, 2026.

New Strong Sell Stocks for January 22nd

MHVYF, NFG and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 22, 2026.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has received a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the stock, MarketBeat.com...

Needham & Company LLC Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price

Needham & Company LLC lowered their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday...

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the...

Autolus Therapeutics (NASDAQ:AUTL) Shares Up 13.5% on Analyst Upgrade

Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade...

Autolus Therapeutics (NASDAQ:AUTL) Given New $11.00 Price Target at Needham & Company LLC

Needham & Company LLC upped their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Monday...

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat.com...

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.46
Prev Close	$1.42
Open	$1.42
Dividend Yield	0.00%
50-Day Moving Average	$1.56
Beta	1.30
Avg. Volume	2.35M
PE Ratio	-1.73

52-Week High	$2.70
52-Week Low	$1.11
Market Capitalization	$388.57M
EPS (Annual)	-$0.8652
Price to Book	1.95
Revenue Per Employee	$15,648.00
Enterprise Value/EBITDA	N/A

AUTL
Autolus Therapeutics Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUTL News

AUTLAutolus Therapeutics Ltd - ADR